Paper17548746
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
Keefe RS and 18 others. Arch Gen Psychiatry, 2007. Cited by 833 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Papers, record 17548746. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17548746
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antipsychotic Agents | Major topic |
| Cognition Disorders | Major topic |
| Neuropsychological Tests | Major topic |
| Schizophrenia | Major topic |
| Schizophrenic Psychology | Major topic |
| Adult | |
| Benzodiazepines | |
| Cohort Studies | |
| Dibenzothiazepines | |
| Double-Blind Method | |
| Female | |
| Humans | |
| Male | |
| Olanzapine | |
| Perphenazine | |
| Piperazines | |
| Quetiapine Fumarate | |
| Risperidone | |
| Thiazoles | |
| Treatment Outcome |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| N01 MH90001 | NIMH NIH HHS | United States | N01MH090001 | PubMed and NIH |
Source NIH RePORTER
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT02634684 | Pharmacologically-augmented Cognitive Therapies (PACTs) for Schizophrenia. | Background | ClinicalTrials.gov | |
| NCT06482918 | Cognitive Remediation in Schizophrenia: Efficacy and Role of Neuroplasticity in "Top-down" and "Bottom-up" Mechanisms | Background | ClinicalTrials.gov |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 17,548,745 | Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. | https://conductscience.org/library/papers/17548745 |
Source PubMed
Cited by424
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 833 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,936,612 | Much of the Neurocognitive Impairment in Schizophrenia is Due to Factors Other Than Schizophrenia Itself: Implications for Research and Treatment. | Schizophr Bull Open | 2021 | https://conductscience.org/library/papers/42936612 | PubMed |
| 42,920,855 | Cognitive remediation in schizophrenia: efficacy and role of neuroplasticity in "top-down" and "bottom-up" mechanisms-a randomized, double-blind, treatment-as-usual-controlled study protocol. | Front Psychiatry | 2026 | https://conductscience.org/library/papers/42920855 | PubMed |
| 42,793,358 | Additive Effects of Cognitive Remediation and Physical Exercise in Patients with Schizophrenia: Cognitive Improvements. | Brain Sci | 2026 | https://conductscience.org/library/papers/42793358 | PubMed |
| 42,488,869 | Repetitive Transcranial Magnetic Stimulation (rTMS) as a Modulator of Cognitive Dysfunction in Schizophrenia: Evidence from a Nigerian Outpatient Cohort. | Niger Med J | 2025 | https://conductscience.org/library/papers/42488869 | PubMed |
| 42,400,655 | Effects of quetiapine on cognitive functioning in schizophrenia: evidence for the remyelination hypothesis? | Eur Arch Psychiatry Clin Neurosci | 2026 | https://conductscience.org/library/papers/42400655 | PubMed |
| 42,383,258 | Cue-induced inhibitory control in forensic patients with alcohol use disorder: A link to criminal recidivism risk assessed by factor 2 psychopathy. | Addict Behav Rep | 2026 | https://conductscience.org/library/papers/42383258 | PubMed |
| 42,253,762 | Cariprazine augmentation for negative symptoms of schizophrenia: a prospective analysis and literature review. | Ther Adv Psychopharmacol | 2026 | https://conductscience.org/library/papers/42253762 | PubMed |
| 42,169,210 | Cultural adaptation of compensatory cognitive training for Nigerian mental health services: a participatory approach balancing fidelity and contextual fit. | Implement Sci Commun | 2026 | https://conductscience.org/library/papers/42169210 | PubMed |
| 41,943,939 | Dynamic frontoparietal flexibility and cognitive dysfunction in schizophrenia: disentangling the roles of symptom burden and childhood trauma. | Psychol Med | 2026 | https://conductscience.org/library/papers/41943939 | PubMed |
| 41,677,693 | Psychosis: The Utility of Ketamine as a Pharmacological Model of Psychotic-like Symptoms in Rodents: A Review of Dosage Regimens. | Biology (Basel) | 2026 | https://conductscience.org/library/papers/41677693 | PubMed |
| 41,629,854 | Living with psychosis and cognitive impairment: a qualitative study. | BMC Psychiatry | 2026 | https://conductscience.org/library/papers/41629854 | PubMed |
| 41,480,735 | Negative association between cognitive functioning and antipsychotic D2 receptor occupancy, affinity, and dose after first episode psychosis. | Psychol Med | 2026 | https://conductscience.org/library/papers/41480735 | PubMed |
| 41,466,278 | Managing schizophrenia with affective, sexual, metabolic and substance-use comorbidities: pharmacological considerations from an expert consensus. | Ann Gen Psychiatry | 2025 | https://conductscience.org/library/papers/41466278 | PubMed |
| 41,421,073 | Neighborhood environmental deprivation predicts the generalized neurocognitive deficit in schizophrenia. | Schizophr Res | 2026 | https://conductscience.org/library/papers/41421073 | PubMed |
| 41,373,230 | Efficacy of Baduanjin Versus Brisk Walking on Cognitive and Physical Functions in Schizophrenia: A Three-Arm Randomized Controlled Trial. | Healthcare (Basel) | 2025 | https://conductscience.org/library/papers/41373230 | PubMed |
| 41,281,533 | Unraveling the mysteries of schizophrenia: Insights into prefrontal cortex dysfunction and therapeutic implications. | World J Psychiatry | 2025 | https://conductscience.org/library/papers/41281533 | PubMed |
| 41,121,094 | Moderating role of familial relationships in the efficacy of rTMS intervention on cognitive function in patients with schizophrenia. | BMC Psychiatry | 2025 | https://conductscience.org/library/papers/41121094 | PubMed |
| 40,807,053 | Targeting Psychotic and Cognitive Dimensions in Clinical High Risk for Psychosis (CHR-P): A Narrative Review. | J Clin Med | 2025 | https://conductscience.org/library/papers/40807053 | PubMed |
| 40,711,497 | Sigma-1 Receptor Activation by Fluvoxamine Ameliorates ER Stress, Synaptic Dysfunction and Behavioral Deficits in a Ketamine Model of Schizophrenia. | J Neuroimmune Pharmacol | 2025 | https://conductscience.org/library/papers/40711497 | PubMed |
| 40,341,586 | The Association Between Psychotropic Medications and Cognitive Functioning in a Real-World Cohort of 869 Individuals with Schizophrenia. | Schizophr Bull | 2026 | https://conductscience.org/library/papers/40341586 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17548746
GET https://conductscience.org/api/papers/v1/17548746/cited_by?page=2